Polymorphisms in cycloxygenase-2 gene and breast cancer prognosis: Association between PTGS2 haplotypes and histopathological features

Breast Cancer Research and Treatment

Volumn 132, Issue 1, 2012, Pages 251-258

  Festa Vasconcellos, Juliana S ^a,b   Piranda, Diogo N ^a,b   Amaral, Laura M ^b   Indio Do Brasil, Vanessa ^b,c   Koifman, Sérgio ^c   Vianna Jorge, Rosane ^a,b  

^a FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

^b Instituto Nacional de Câncer INCA   (Brazil)

^c INSTITUTO OSWALDO CRUZ   (Brazil)

Author keywords

Breast cancer; COX 2; Haplotypes; Histopathological features; Polymorphisms; PTGS2

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR;

ADULT; ARTICLE; BREAST CANCER; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER SIZE; CLINICAL EVALUATION; CONTROLLED STUDY; CYCLOOXYGENASE 2 GENE; FEMALE; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC VARIABILITY; HAPLOTYPE; HIGH RISK PATIENT; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RECURRENCE RISK; TUMOR GENE;

ADOLESCENT; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CARCINOMA, LOBULAR; CASE-CONTROL STUDIES; CYCLOOXYGENASE 2; FEMALE; GENETIC ASSOCIATION STUDIES; HAPLOTYPES; HUMANS; NEOPLASM GRADING; POLYMORPHISM, SINGLE NUCLEOTIDE; PROGNOSIS; RECEPTORS, STEROID; SEQUENCE ANALYSIS, DNA; TUMOR BURDEN;

EID: 84857920421     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-011-1828-0     Document Type: Article

References (52)

1. Ferlay J, Shin HR, Bray F et al (2010) Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 127:2893-2917
2. Hayes DF, Isaacs C, Stearns V (2001) Prognostic factors in breast cancer: current and new predictors of metastasis. J Mammary Gland Biol Neoplasia 6:375-392
3. Needleman P, Turk J, Jakschik BA, Morrison AR, Lefkowith JB (1986) Arachidonic acid metabolism. Annu Rev Biochem 55:69-102 (Pubitemid 16070764)
4. Harris RE, Chlebowski RT, Jackson RD et al (2003) Breast cancer and nonsteroidal anti-inflammatory drugs: prospective results from the Women's Health Initiative. Cancer Res 63:6096-6101 (Pubitemid 37187516)
5. Khuder SA, Mutgi AB (2001) Breast cancer and NSAID use: a meta-analysis. Br J Cancer 84:1188-1192 (Pubitemid 32511336)
6. Papafili A, Hill MR, Brull DJ et al (2002) Common promoter variant in cyclooxygenase-2 repress gene expression. Arterioscler Thromb Vasc Biol 22:1631-1636
7. Zhang X, Miao X, Tan W et al (2005) Identification of functional genetic variants in cyclooxygenase-2 and their association with risk of esophageal cancer. Gastroenterology 129:565-576 (Pubitemid 41096644)
8. Caput D, Beutler B, Hartog K et al (1986) Identification of a common nucleotide sequence in the 3′-untranslated region of RNA molecules specifying inflammatory mediators. Proc Natl Acad Sci USA 83:1670-1674 (Pubitemid 16018626)
9. Di Marco S, Hel Z, Lachance C, Furneaux H, Radzioch D (2001) Polymorphism in the 3′-untranslated region of TNFα mRNA impairs binding of the posttranscriptional regulatory protein HuR to TNFα mRNA. Nucleic Acid Res 29:863-871 (Pubitemid 32162253)
10. Kristinsson J, Westerveld PV, Rene HM et al (2009) Cyclooxygenase-2 polymorphisms and the risk of esophageal adeno- or squamous cell carcinoma. World J Gastroenterol 15:3493-3497
11. Upadhyaya R, Jain M, Kumarb S, Ghoshalc UC, Mittala B (2009) Functional polymorphisms of cyclooxygenase-2 (COX-2) gene and risk for esophageal squmaous cell carcinoma. Mutat Res 663:52-59
12. Hou L, Grillo P, Zhu ZZ et al (2007) COX1 and COX2 polymorphisms and gastric cancer risk in a Polish population. Anticancer Res 27:4243-4247
13. Liu F, Pan K, Zhang X et al (2006) Genetic variants in cyclooxygenase-2: expression and risk of gastric cancer and its precursors in a Chinese population. Gastroenterology 130:1975-1984 (Pubitemid 43816953)
14. Panguluri RCK, Long LO, Chen W et al (2004) COX-2 gene promoter haplotypes and prostate cancer risk. Carcinogenesis 25:961-966 (Pubitemid 38886082)
15. Shahedi K, Lindström S, Zheng SL et al (2006) Genetic variation in the COX-2 gene and the association with prostate cancer risk. Int J Cancer 119:668-672 (Pubitemid 43955722)
16. Cheng I, Liu X, Plummer SJ et al (2007) COX-2 genetic variation, NSAIDs, and advanced prostate cancer risk. Br J Cancer 97:557-561 (Pubitemid 47258446)
17. Danforth KN, Hayes RB, Rodriguez C et al (2008) Polymorphic variants in PTGS2 and prostate cancer risk: results from two large nested case-control studies. Carcinogenesis 29:568-572 (Pubitemid 351404873)
18. Zhang J, Dhakal IB, Lang NP, Kadlubar FF (2010) Polymorphisms in inflammatory genes, plasma antioxidants, and prostate cancer risk. Cancer Causes Control 21:1437-1444
19. Cox DG, Pontes C, Guino E et al (2004) Polymorphisms in prostaglandin synthase 2/cyclooxygenase 2 (PTGS2/COX2) and risk of colorectal cancer. Br J Cancer 91:339-343 (Pubitemid 39037081)
20. Ali IU, Luke BT, Dean M, Greenwald P (2005) Allellic variants in regulatory regions of cyclooxygenase-2: association with advanced colorectal adenoma. Br J Cancer 93:953-959 (Pubitemid 41487024)
21. Ulrich CM, Whitton J, Yu JH et al (2005) PTGS2 (COX-2)-765G > C promoter variant reduces risk of colorectal adenoma among nonusers of nonsteroidal anti inflammatory drugs. Cancer Epidemiol Biomarkers Prev 14:616-619 (Pubitemid 40489204)
22. Tan W, Wu J, Zhang X et al (2007) Associations of functional polymorphisms in cyclooxygenase-2 and platelet 12-lipoxygenase with risk of occurrence and advanced disease status of colorectal cancer. Carcinogenesis 28:1197-1201 (Pubitemid 47064309)
23. Campa D, Zienolddiny S, Maggini V et al (2004) Association of a common polymorphism in the cyclooxygenase 2 gene with risk of non-small cell lung cancer. Carcinogenesis 25:229-235 (Pubitemid 38239806)
24. Sorensen M, Autrup H, Tjonneland A, Overvad K, Raaschou-Nielsen O et al (2005) A genetic polymorphism in prostaglandin synthase 2 (8473, T/C) and the risk of lung cancer. Cancer Lett 226:49-54 (Pubitemid 40943429)
25. Moorman PG, Sesay J, Nwosu V et al (2005) Cyclooxygenase 2 polymorphism (Val511Ala), nonsteroidal anti-inflammatory drug use and breast cancer in African American women. Cancer Epidemiol Biomarkers Prev 14:3013-3014 (Pubitemid 43068842)
26. Shen J, Gammon MD, Terry MB et al (2006) Genetic polymorphisms in the cyclooxygenase-2 gene, use of nonsteroidal anti-inflammatory drugs, and breast cancer risk. Breast Cancer Res. doi:10.1186/bcr1629
27. Langsenlehner U, Yazdani-Biuki B, Eder T et al (2006) The cyclooxygenase-2 (PTGS2) 8473T>C polymorphism is associated with breast cancer risk. Clin Cancer Res 12:1392-1394 (Pubitemid 43342533)
28. Gallicchio L, Mcsorley MA, Newschaffer CJ et al (2006) Non-steroidal antiinflammatory drugs, cyclooxygenase polymorphisms, and the risk of developing breast carcinoma among women with benign breast disease. Cancer 106:1443-1452
29. Cox DG, Buring J, Hankinson SE, Hunter DJ (2007) A polymorphism in the 30untranslated region of the gene encoding prostaglandin endoperoxide synthase 2 is not associated with an increase in breast cancer risk: a nested case-control study. Breast Cancer Res. doi:10.1186/bcr1635
30. Abraham JE, Harrington P, Driver KE et al (2009) Common polymorphisms in the prostaglandin pathway genes and their association with breast cancer susceptibility and survival. Clin Cancer Res 15:2181-2191
31. Li F, Ren GS, Li HY et al (2009) A novel single nucleotide polymorphism of the cyclooxygenase-2 gene associated with breast cancer. Clin Oncol 21:302-305
32. Dossus L, Kaaks R, Canzian F et al (2009) PTGS2 and IL6 genetic variation and risk of breast and prostate cancer: results from the breast and prostate cancer cohort consortium (BPC3). Carcinogenesis 31:455-461
33. Piranda DN, Festa-Vasconcellos JS, Murta L, Bergmann A, Vianna-Jorge R (2010) Polymorphisms in regulatory regions of Cyclooxygenase-2 gene and breast cancer risk in Brazilians: a case-control study. BMC Cancer. doi:10.1186/1471-2407-10-613
34. Brasky TM, Bonner MR, Moysich KB et al (2011) Genetic variants in COX2, non-steroidal anti-inflammatory drugs and breast cancer risk: the Western New York Exposures and Breast Cancer Study. Breast Cancer Res Treat 126:157-165
35. Ke-Da Yu, Chen Ao-Xiang, Yang Chen et al (2010) Current evidence on the relationship between polymorphisms in the COX-2 gene and breast cancer risk: a meta-analysis. Breast Cancer Res Treat 122:251-257
36. Zhu W, Wei BB, Shan X, Liu P (2010) 765G/C and 8473T/C polymorphisms of COX-2 and cancer risk: a meta-analysis based on 33 case-control studies. Mol Biol Rep 37:277-288
37. Lester SC, Bose S, Chen YY et al (2009) Protocol for the examination of specimens from patients with invasive carcinoma of the breast. Arch Pathol Lab Med 133:1515-1538
38. Elston CW, Ellis IO (1991) Pathological prognostic factors in breast cancer. The value of histological grades in breast cancer: experience from a large study with long-term follow-up. Histopathology 19:403-410
39. Barrett JC, Fry B, Maller J, Daly MJ (2005) Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics 21:263-265 (Pubitemid 40202029)
40. Dixon DA, Kaplan CD, McIntyre TM, Zimmerman GA, Prescott SM (2000) Posttranscriptional control of cyclooxygenase-2 gene expression. J Biol Chem 275(16):11750-11757
41. Szczeklik W, Sanak M, Szczeklik A (2004) Functional effects and gender association of COX-2 gene polymorphism G-765C in bronchial Asthma. J Allergy Clin Immunol 114(2):248-253 (Pubitemid 39119020)
42. Moore AE, Young LE, Dixon DA (2011) A common single-nucleotide polymorphism in cyclooxygenase-2 disrupts microRNA-mediated regulation. Oncogene. doi: 10.1038/onc.2011.349
43. Gangwar R, Mandhani A, Mittal RD (2011) Functional polymorphisms of cyclooxygenase-2 (COX-2) gene and risk for urinary bladder cancer in North India. Surgery 149:126-134
44. Sanak M, Szczeklik W, Szczeklik A (2005) Association of COX-2 gene haplotypes with prostaglandins production in bronchial asthma. J Allergy Clin Immunol 116:221-223 (Pubitemid 40909772)
45. Lari SA, Kuerer HM (2011) Biological markers in DCIS and risk of breast recurrence: a systematic review. J Cancer 2:232-261
46. Wright C, Angus B, Nicholson S et al (1989) Expression of c-erbB-2 oncoprotein: a prognostic indicator in human breast cancer. Cancer Res 49:2087-2090
47. Borg A, Tandon AK, Sigurdsson H et al (1990) HER-2/neu amplification predicts poor survival in node-positive breast cancer. Cancer Res 50:4332-4337 (Pubitemid 20225674)
48. Toikkanen S, Helin H, Isola J, Joensuu H (1992) Prognostic significance of HER-2 oncoprotein expression in breast cancer: a 30 year follow-up. J Clin Oncol 7:1044-1048
49. Gerger A, Renner W, Langsenlehner T et al (2010) Association of interleukin-10 gene variation with breast cancer prognosis. Breast Cancer Res Treat. 119:701-705
50. Perou CM, Sørlie T, Eisen MB et al (2000) Molecular portraits of human breast tumours. Nature 406(6797):747-752
51. Sørlie T, Perou CM, Tibshirani R et al (2001) Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 98(19):10869-10874
52. Sorlie T, Tibshirani R, Parker J et al (2003) Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci USA 100(14):8418-8423 (Pubitemid 36842560)